Gleevec (imatinib mesylate) in 16 patients with chronic myelomonocytic leukemia (CMMoL).

被引：0
|
作者：
Raza, A [1 ]
Lisak, L [1 ]
Dutt, D [1 ]
Syed, E [1 ]
Dean, L [1 ]
Fantroy, L [1 ]
Gezer, S [1 ]
Reddy, P [1 ]
Hsu, WT [1 ]
Goldberg, C [1 ]
Loew, J [1 ]
Venugopal, P [1 ]
机构：
[1] Rush Univ, MDS Ctr, Chicago, IL 60612 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4829
引用
收藏
页码：273B / 273B
页数：1
相关论文
共 50 条
  • [41] IMATINIB MESYLATE IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Iordache, M.
    Cheveresan, L.
    Ionita, M.
    Borzak, G.
    Ionita, C. O.
    Pascalau, A.
    Calamar, D.
    Oros, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 548 - 548
  • [42] Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study
    Rousselot, Philippe
    Cony-Makhoul, Pascale
    Nicolini, Franck
    Mahon, Francois Xavier
    Berthou, Christian
    Rea, Delphine
    Reiffers, Josy
    Bornand, Anne
    Saint-Jean, Olivier
    Guilhot, Joelle
    Guilhot, Francois
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (01) : 1 - 4
  • [43] Elevations in Creatine Kinase Occur Frequently in Patients Treated with Imatinib Mesylate (Gleevec)
    Gordon, Jessica K.
    Magid, Steven K.
    Berman, Ellin
    ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 3982 - 3982
  • [44] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Shan, J
    Giles, F
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Rios, MB
    Kantarjian, H
    CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3425 - 3432
  • [45] Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate
    Yoon, Ju-Yoon
    Kumar, Rajat
    Aloyz, Raquel
    Johnston, James B.
    LEUKEMIA RESEARCH, 2011, 35 (09) : E179 - E180
  • [46] Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor
    Hasan Şenol Coşkun
    Sema Sezgin Göksu
    Mehmet Şahin
    Güçhan Alanoğlu
    Medical Oncology, 2008, 25 : 110 - 112
  • [47] Imatinib mesylate -: A new pill for chronic myelogenous leukemia
    Parmar, KK
    King, RS
    CANCER PRACTICE, 2001, 9 (05) : 263 - 265
  • [48] Results of imatinib mesylate therapy in chronic myeloid leukemia
    Altintas, Abdullah
    Cil, Timucin
    Ayyildiz, Orhan
    Kaplan, Mehmet A.
    Isikdogan, Abdurrahman
    Muftuoglu, Ekrem
    Atay, Ahmet E.
    ANNALS OF ONCOLOGY, 2006, 17 : 211 - 211
  • [49] Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia
    Rastogi, Maynika V.
    Stork, Linda
    Druker, Brian
    Blasdel, Carolyn
    Thuan Nguyen
    Boston, Bruce A.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (05) : 840 - 845
  • [50] Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
    Akay, Olga Meltem
    Mutlu, Fezan
    Gulbas, Zafer
    TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) : 127 - 130
12345